Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice | Zendy

Debby Wensink | Zendy; Margreet A. E. M. Wagenmakers | Zendy; Jasmin BarmanAksözen | Zendy; Edith C. H. Friesema | Zendy; J. H. P. Wilson | Zendy; Joost van Rosmalen | Zendy; Janneke G. Langendonk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice

Author(s) -

Debby Wensink,

Margreet A. E. M. Wagenmakers,

Jasmin BarmanAksözen,

Edith C. H. Friesema,

J. H. P. Wilson,

Joost van Rosmalen,

Janneke G. Langendonk

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.0352

Subject(s) - medicine , interquartile range , quality of life (healthcare) , adverse effect , prospective cohort study , erythropoietic protoporphyria , clinical practice , physical therapy , chemistry , porphyrin , photochemistry , protoporphyrin , nursing

The effectiveness of afamelanotide treatment in patients with erythropoietic protoporphyria (EPP) in clinical practice who experience pain after light exposure that substantially impairs quality of life is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research